Latest News in the pharma Industry

Research & Development

New Source of Cells for Modeling Malaria

New Source of Cells for Modeling Malaria

6 Feb 2015

Read more 
Genentech’s Phase III Study of Gazyva Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

Genentech’s Phase III Study of Gazyva Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma

4 Feb 2015

Read more 
Pierre Fabre Pharmaceuticals Initiates Phase IIa Clinical Trial Programme for F17464 in Schizophrenia

Pierre Fabre Pharmaceuticals Initiates Phase IIa Clinical Trial Programme for F17464 in Schizophrenia

3 Feb 2015

Read more 
Novel Organoid Matrix Enables Long-Term Culture of Human Hepatocytes

Novel Organoid Matrix Enables Long-Term Culture of Human Hepatocytes

30 Jan 2015

Read more 
Regeneron and Sanofi Announce Praluent BLA has Been Accepted for Priority Review by FDA

Regeneron and Sanofi Announce Praluent BLA has Been Accepted for Priority Review by FDA

26 Jan 2015

Read more 
Clinical Studies Gain Pace as Pharmaceutical Industry Helps to Wage War on Diabetes Pandemic

Clinical Studies Gain Pace as Pharmaceutical Industry Helps to Wage War on Diabetes Pandemic

23 Jan 2015

Read more 
Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia

Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia

21 Jan 2015

Read more 
Amgen Presents New Data Supporting First-Line Use of Vectibix in Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer

Amgen Presents New Data Supporting First-Line Use of Vectibix in Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer

19 Jan 2015

Read more 
Lilly and Merck Collaborate to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer

Lilly and Merck Collaborate to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer

15 Jan 2015

Read more 
BMS and Lilly Set to Collaborate to Evaluate Opdivo in Combination with Galunisertib in Advanced Solid Tumours

BMS and Lilly Set to Collaborate to Evaluate Opdivo in Combination with Galunisertib in Advanced Solid Tumours

14 Jan 2015

Read more 
Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome

Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome

13 Jan 2015

Read more 
Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology

Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology

12 Jan 2015

Read more